Consolidated Financial Performance - Q2 FY27

  • Total Revenue: ₹828.8 crore, increased 27% YoY from ₹652.9 crore in Q2 FY26
  • Gross Profit: ₹329.7 crore, increased 35% YoY from ₹244.6 crore
  • EBITDA: ₹137.9 crore, increased 63% YoY from ₹84.4 crore
  • EBITDA Margin: 16.6%, expanded 370 basis points YoY from 12.9%
  • Profit After Tax (PAT): ₹82.8 crore, increased 83% YoY from ₹45.2 crore
  • PAT Margin: 10.0%, expanded 310 basis points YoY from 6.9%
  • EPS: ₹9.07, increased 83% YoY from ₹4.95

Consolidated Financial Performance - H1 FY27

  • Total Revenue: ₹1,532.4 crore, increased 23% YoY from ₹1,243.7 crore in H1 FY26
  • Gross Profit: ₹605.7 crore, increased 31% YoY from ₹462.0 crore
  • EBITDA: ₹234.8 crore, increased 48% YoY from ₹158.8 crore
  • EBITDA Margin: 15.3%, expanded 250 basis points YoY from 12.8%
  • Profit After Tax (PAT): ₹132.9 crore, increased 34% YoY from ₹99.1 crore
  • PAT Margin: 8.7%, expanded 70 basis points YoY from 8.0%
  • EPS: ₹14.56, increased 34% YoY from ₹10.86

Segmental Performance - Q2 FY27

  • API: ₹604.5 crore, increased 17% YoY from ₹515.9 crore
  • Formulation: ₹130.0 crore, increased 58% YoY from ₹82.4 crore
  • Specialty Chemicals: ₹71.8 crore, increased 92% YoY from ₹37.3 crore
  • Intermediates & Others: ₹19.9 crore, increased 16% YoY from ₹17.1 crore

Segmental Performance - H1 FY27

  • API: ₹1,115.0 crore, increased 14% YoY from ₹974.1 crore
  • Formulation: ₹216.3 crore, increased 33% YoY from ₹162.8 crore
  • Specialty Chemicals: ₹154.3 crore, increased 119% YoY from ₹70.4 crore
  • Intermediates & Others: ₹43.4 crore, increased 20% YoY from ₹36.1 crore

Standalone Business Highlights - Q2 FY27

  • Revenue: ₹708.9 crore, increased 22% YoY from ₹579.0 crore
  • Contribution to consolidated revenue: 86%
  • Domestic market contribution: 68% of standalone revenue
  • Export market contribution: 32% of standalone revenue
  • Domestic revenue growth: 43% YoY
  • Export revenue growth: -5% YoY

API Business Breakdown - Q2 FY27

  • Anti-biotic therapeutic category: 34.1% of total API sales
  • Anti-protozoal: 18.1% of total API sales
  • Anti-inflammatory: 14.8% of total API sales
  • Anti-diabetic: 18.2% of total API sales
  • Antifungal: 9.3% of total API sales
  • Others: 5.6% of total API sales

Formulation Segment Performance

  • Q2 FY27 Revenue: ₹130.0 crore (exports contributed 74%)
  • H1 FY27 Revenue: ₹211.7 crore (exports contributed 63%)

Management Commentary

Mr. Adhish Patil, Managing Director, stated that Q2 FY27 was a landmark quarter with highest-ever revenue from operations of ₹826 crore and highest-ever quarterly EBITDA of ₹138 crore. EBITDA margin of 16.6% is the highest level in nearly six years. Growth was broad-based across businesses with Specialty Chemicals nearly doubling and Formulations growing 58%. The Sayakha facility is meeting significant metformin intermediate requirements in-house. Capacity expansions at Tarapur, Sarigam and Baddi, including new USFDA-compliant capacity, are progressing well.

Leadership Changes

Effective October 1, 2026, Mr. Prakash M. Patil retired as Chairman, Managing Director and CEO. Mr. Rashesh Gogri took over as Chairman and Mr. Adhish Patil as Managing Director.

Company Background

Aarti Drugs Limited was established in 1984 and is part of the $6 Billion Aarti Group of Industries. The company manufactures Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and Formulations through its wholly-owned subsidiary Pinnacle Life Science Private Limited. The company has 14 manufacturing facilities (10 in Maharashtra, 3 in Gujarat, 1 in Himachal Pradesh).